Citatuzumab
Citatuzumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Immunomedics Inc.
History[edit | edit source]
Citatuzumab was one of the many drugs developed by Immunomedics Inc., a company that specializes in the development of monoclonal antibody-based products for the targeted treatment of cancer. The drug was designed to target and destroy cancer cells while sparing healthy cells, a common goal in cancer treatment.
Mechanism of Action[edit | edit source]
As a monoclonal antibody, Citatuzumab works by binding to specific proteins on the surface of cancer cells. This binding triggers the immune system to attack and destroy the cancer cells. The specific target of Citatuzumab is not publicly disclosed.
Clinical Trials[edit | edit source]
Citatuzumab has undergone various clinical trials to test its safety and efficacy in treating cancer. The results of these trials are not publicly available.
See Also[edit | edit source]
References[edit | edit source]
| Citatuzumab Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
